Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

2.6K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

906
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
906
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Protein-Drug Binding: Mechanism and Kinetics01:16

Protein-Drug Binding: Mechanism and Kinetics

2.0K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
2.0K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.8K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference.

Clinical kidney journal·2021
Same author

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

British journal of pharmacology·2021
Same author

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Circulation·2021
Same author

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN·2021
Same author

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Nature reviews. Nephrology·2021
Same author

Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.

Hypertension (Dallas, Tex. : 1979)·2021
Same journal

Applying Lean principles to clinic operations.

Nephrology news & issues·2019
Same journal

Practical approaches to iron therapy.

Nephrology news & issues·2019
Same journal

Recreational use of marijuana: Current experience and information for nephrologists.

Nephrology news & issues·2019
Same journal

Emerging treatments for anemia in patients with CKD and ESRD.

Nephrology news & issues·2019
Same journal

Reflections at the end of a career in dialysis.

Nephrology news & issues·2019
Same journal

The emerging role of the cardio-renal physician.

Nephrology news & issues·2019
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
10:07

High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

Published on: January 27, 2013

15.7K

Current and future potassium binders

George L Bakris

    Nephrology News & Issues
    |June 4, 2016
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
    11:20

    Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

    Published on: May 7, 2018

    12.8K
    Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
    10:08

    Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

    Published on: December 9, 2022

    2.7K

    Related Experiment Videos

    Last Updated: Mar 20, 2026

    High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels
    10:07

    High-throughput Screening for Small-molecule Modulators of Inward Rectifier Potassium Channels

    Published on: January 27, 2013

    15.7K
    Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain
    11:20

    Making, Testing, and Using Potassium Ion Selective Microelectrodes in Tissue Slices of Adult Brain

    Published on: May 7, 2018

    12.8K
    Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting
    10:08

    Study of the Functions and Activities of Neuronal K-Cl Co-Transporter KCC2 Using Western Blotting

    Published on: December 9, 2022

    2.7K